Screener
Madrigal Pharmaceuticals, Inc. MDGL Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Loss from operations | (56,308) | (47,202) | (149,031) | (126,513) |
| Interest income | 7,104 | 8,227 | 15,347 | 17,597 |
| Interest expense | (7,940) | (3,264) | (15,759) | (6,561) |
| Other expense, net | (795) | (42) | (2,887) | (42) |
| Net loss | $(57,939) | $(42,281) | $(152,330) | $(115,519) |
| Net loss per common, Series A preferred and Series B preferred share: | ||||
| Basic and diluted net loss per common, Series A preferred, and Series B preferred share | $(1.99) | $(1.50) | $(5.24) | $(4.10) |
| Basic and diluted weighted average number of shares outstanding (Note 13) | 29,145,271 | 28,232,604 | 29,089,148 | 28,159,333 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s other income, net (note 6)?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported other income, net (note 6) of -$795K in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s other income, net (note 6) changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s other income, net (note 6) decreased by 1792.9% year-over-year, from -$42K to -$795K.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude